UK govt warned against Internet cancer drugs

4 May 2008

The UK government has been warned by the parliamentary group on cancer that more British people are buying drugs via the Internet which offer unproven benefits against the disease. A report in the Guardian newspaper states that dichloroacetate (DCA) is being offered to patients on the basis of animal research data published in the Cancer Cell journal in early 2007.

Jim Tassano, the owner of a California, USA-based pest control company which sells the drug, told the Guardian that he is wary of making any public claims about any alleged benefits of DCA, because the Food and Drug Administration cracks down on the promotion of active ingredients for unlicensed purposes. Kat Arney, a spokeswoman for Cancer Research UK, described the case as "probably the worst thing possible." Dr Arney added that people taking DCA may be vulnerable to adverse effects.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight